Print Page   |   Contact Us   |   Sign In   |   Create a Profile
News & Press: Industry News

CorMatrix® Cardiovascular, Inc. Secures Twelve (12) Additional U.S. Patents for ECM® Biomaterial

Wednesday, March 04, 2015   (0 Comments)
Posted by: Angela King
Share |

CorMatrix® Bolsters Its Existing Patent Protections with Newly Issued Patents

ROSWELL, Ga.--(BUSINESS WIRE)--CorMatrix® Cardiovascular, Inc., a leading developer of biomaterials and medical devices, today announced the issuance of U.S. Patent Numbers: 8,568,761; 8,753,885; 8,734,841; 8,642,084; 8,771,737; 8,734,842; 8,753,886; 8,735,155; 8,771,737; 8,784,891; 8,785,197 and 8,785,198 directed to CorMatrix’s novel augmented extracellular matrix (ECM®) bioscaffolds.

The augmented ECM® bioscaffold tissue structures comprise various materials, including, but not limited to, small intestine, urinary bladder, liver, stomach, placental, and heart tissue, that are augmented with a variety of selective bioactive components, such as GAGs, FGF-2, TGF-α, TFG-β, VEGF, cytokines and DNA. The augmented ECM® bioscaffolds, when administered to damaged tissue, induce stem cell proliferation and differentiation of stem cells into cardiomyocytes and, thereby, angiogenesis and remodeling of the damaged tissue.

“Since our founding in 2001, CorMatrix has focused on bringing innovation to the science of ECM® and ECM® technologies. Our success in securing these patents will help us to expand the effectiveness, scope, and potential of ECM® while guiding us in other restorative tissue advancements. We continue to pursue these and other patents globally with the intent of creating innovative healthcare products patients receive as part of their treatment, and the ultimate goal of improving their quality of life,” said David Camp, CEO and co-founder of CorMatrix.

With this and other significant patent protection, CorMatrix is poised to successfully expand its current line of product offerings with over 230 pending U.S. and foreign patent applications directed to various ECM® based compositions and structures. In addition to the recently issued patents for CorMatrix’s novel augmented injectable extracellular matrix (ECM®) bioscaffolds, in the last two years alone over thirty (30) U.S. and foreign patents have issued for CorMatrix’s ECM® based compositions and structures, including U.S. Patent Nos. 8,871,511, 8,778,012, 8,758,448, 8,709,076, 8,257,434, 8,409,275, 8,679,176, 8, 449,607,8,608,796, 8,696,7448,845,719, 8,808,363, D718,862, D718,863, D718,864D694,408, D688,372, European Community Pat. Nos. EC 002455907-0001, European Community Pat. Nos. EC 002455907-0002, Japan Pat. Nos. JP 1514306, JP 1514307, and South Africa Pat. No. ZA 2011/06165.

About CorMatrix

CorMatrix® Cardiovascular, Inc. is a privately held medical device company dedicated to developing and delivering innovative biomaterial devices that harness the body’s own innate ability to repair damaged cardiac and vascular tissues. CorMatrix ECM Technology® allows surgeons to restore the native anatomy of cardiac and vascular tissue in need of repair, serving as a superior alternative to synthetic or cross-linked materials. Headquartered in Roswell, Georgia, the Company is currently researching, developing and commercializing a platform technology known as CorMatrix ECM® for a variety of cardiovascular and other indications, and has U.S. clearance and European registration (with a CE Mark) for its ECM Technology®. Since its launch in 2006, CorMatrix ECM Technology® has been used at more than 825 hospitals across the U.S. and has been implanted in over 100,000 cardiac procedures. Visit for additional information.


CorMatrix Cardiovascular, Inc.
Stephanie Beall, 470-514-4031

Source: BusinessWire:

more Calendar

Careers in Life Sciences Series: Finance, Consulting and Business

Membership Software Powered by®  ::  Legal